 Home > Medical News > Latest Medical News > Keytruda/Lenvima Combination Phase 3 Trial Announces Full Results

Keytruda/Lenvima Combination Phase 3 Trial Announces Full Results

 Last Update: 2022-03-09
 Source: Internet
 Author: User

Tags

proseal plus

journal software

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

A few days ago, Merck & Co.
(MSD) and Eisai (Eisai) announced positive results from a pivotal Phase 3 clinical trial in the New England Journal of Medicine
.

Trial results met its dual primary endpoint of overall survival (OS) compared with chemotherapy in patients with advanced endometrial cancer treated with the anti-PD-1 therapy Keytruda in combination with the oral multi-receptor tyrosine kinase inhibitor Lenvima and progression-free survival (PFS) showed significant improvement

Endometrial cancer is the most common type of cancer in the uterus
.

In 2020, there are estimated to be more than 417,000 new cases globally

The Keytruda/Lenvima combination therapy is an important cancer immune combination therapy jointly developed by Merck and Eisai
.

Keytruda is a humanized monoclonal antibody that blocks PD-1-mediated immunosuppressive signaling, thereby activating T lymphocytes and increasing the body's immune system's ability to find and fight tumor cells

In this phase 3 clinical trial, 827 patients were randomized 1:1 to receive Keytruda + Lenvima, or chemotherapy (doxorubicin or paclitaxel)
.

Trial data showed that the Keytruda/Lenvima group had significantly higher median PFS (7.
2 months vs.
3.
8 months) and median OS (18.
3 months vs.
11.
4 months) compared to the chemotherapy group
.

In terms of safety, 88.

References:

[1] Results From Pivotal Phase 3 KEYNOTE-775/Study 309 Trial of KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Advanced Endometrial Carcinoma Published in the New England Journal of Medicine.

[2] Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.